Filgotinib in ulcerative colitis in clinical practice: real-world data published in 2025

Czech version

Authors: M. Lukáš ¹; M. Lukáš jr. ^1,2
Authors‘ workplace: Klinické a výzkumné centrum pro střevní záněty, Klinické centrum ISCARE a. s. a 1. LF UK v Praze ¹; Klinické a výzkumné centrum pro střevní záněty, Klinické centrum ISCARE a. s. a 3. LF UK v Praze ²
Published in: Gastroent Hepatol 2025; 79(6): 483-487
Category: IBD
doi: https://doi.org/10.48095/ccgh2025483

Overview

Filgotinib is a preferential JAK-1 inhibitor, which was introduced in clinical practice in ulcerative colitis patients in 2022. In that year, many real-world clinical data have been published, documenting that filgotinib therapy is associated with high efficacy and safety. The most important project in real clinical practice is the GALOCEAN study, from which the first preliminary data have been presented. Clinical practice confirmed that the anti-inflammatory efficacy of filgotinib is similar to tofacitinib, but slightly lower than upadacitinib. Compared to upadacitinib and tofacitinib, long-term therapy with filgotinib is associated with a lower frequency of side effects.

Keywords:

filgotinib – ulcerative colitis – JAK inhibitors – upadacitinib – tofacitinib

Sources

1. Seenan JP, Hoevik ML, Vermeire S et al. Filgotinib effectiveness and safety in moderate and severely active patients with ulcerative colitis: early real-world outcomes and an interim analysis a data from the prospective, observational GALOCEAN study. J Crohns Colitis 2025; 19 (Suppl 1): i2087–i2088. doi: 10.1093/ecco-jcc/jjae 190.1314.

2. Danese S, Argollo M, Le Berre C, Peyrin-Birouleth L. JAK selectivity for inflammatory bowel disease: does it clinical matter? GUT 2019; 68 : 1893–1899.

3. Hoevik ML, Vermeire S, Reinisch W et al. Real-world effectiveness and safety of filgotinib with and without concomitant therapies in patients with ulcerative colitis an interim analysis from the prospective, observational GALOCEAN study. J Crohns Colitis 2025; 19 (Suppl 1): i1884–i1885. doi: 10.1093/ecco-jcc/jjae 190.1191.

4. Buisson A, Treton X, Nachury M et al. Effectiveness comparison between tofacitinin, filgotinib and upadacitinib in ulcerative colitis: results from the JAKARTA: real-world evidence of multicentre study. J Crohns Colitis 2025; 169 (1): S1516. doi: 10.1016/S0016-5085 (25) 04366-5.

5. Yagi S, Fukui H, Ikenouchi M et al. Effectivenes of tofacitinib and filgotinib as an induction therapy for ptients with moderate to severe ulcerative colitis: real-world comparison in propensity score matching analysis. J Crohns Colitis 2025; 19 (Suppl 1): i1522. doi: 10.1093/ecco-jcc/jjae190.0964.

6. Kumar A, Baxter J, Rimmer P et al. A multi-centered retrospective cohort study comparing JAK inhibitor therapies in moderate to severe ulcerative colitis. J Crohns Colitis 2025; 19 (Suppl 1): i2143.

7. Feagan BG, Danese S, Loftus EV et al. Filgotinib as induction and maintenance therapy for ulcerative colitis (SELECTION): a phase 2b/3 double-blind, randomised, placebo-controlled trial. Lancet 2021; 397 (10292): 2372–2384. doi: 10.1016/S0140-6736 (21) 00666-8.

8. Pruijt MJ, Teichert C, de Voogd FA et al. Kinetics of intestinal ultrasound and shear vawe elastography to assess early response in ulcerative colitis patients treated with filgotinib. J Crohns Colitis 2025; jjaf185. doi: 10.1093/ecco-jcc/jjaf185.

9. Uchino M, Ikeuchi H, Horio Y et al. The short-term efficacy of of filgotinib on antibiotic dependent/resistant pouchitis in patients with ulcerative colitis. J Crohns Colitis 2025; 19 (Suppl 1): i1517. doi: 10.1093/ecco-jcc/jjae190.0960.

10. Allez M, Burisch J, Verstockt B et al. Effect of baseline diasese severity achieving efficacy endpoints in patients with ulcerative colitis treated with filgotinib. J Crohns Colitis 2025; 19 (Suppl 1): i2094–i2096. doi: 10.1093/ecco -⁠ jcc/jjae190.1318.

11. Osty M, Altwegg R, Serrero M et al. Efficacy and safety of a second JAK inhibitor in ulcerative colitis: the J2J multicenter cohort. J Crohns Colitis 2025; 62 (4): 430–439. doi: 10.1111/apt.70199.

12. Nogami A, Asonuma K, Okabayashi S et al. Real-world comparative safety of filgotinib and upadacitinib for ulcerative colitis: a propensite score matching. J Crohns Colitis 2025; 19 (Suppl 1): i2117–i2118. doi: 10.1093/ecco-jcc/ jjae190.1334.

13. Naber M, van der Meulen A, Voorneveld P et al. Real-world effectiveness and safety of filgotinib in ulcerative colitids: 1 year of follow up results of the ICC registry. J Crohns Colitis 2025; 19 (Suppl 1): i1782–i1783. doi: 10.1093/ecco-jcc/jjae190.1127.

14. Gonzales-Lama Y, Calvo M, Alfageme F et al. Incidence, risk factors, and management of acne in IBD patients on JAK inhibitors: a multicentre, retrospective cohort study (the JAKNE project). J Crohns Colitis 2025; 19 (Suppl 1): i1712. doi: 10.1093/ecco-jcc/jjae190.1079.